Evidence map›Paper›PMID 33294421›Full record

ArticleImmunoTargets and therapy2020

Development of Anti-

Antonietta M Lillo, Nileena Velappan, Julia M Kelliher, Austin J Watts, Samuel P Merriman, Grace Vuyisich, Laura M Lilley, Kent E Coombs, Tara Mastren, Munehiro Teshima and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ImmunoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. In Vitro Selection of Antibodies TargetingPathogens (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Development ofACS omega · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Optimised Heterologous Expression and Functional Analysis of theInternational journal of molecular sciences · 2021
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Antonietta M LilloBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0002-0457-6598
Nileena VelappanBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0002-4488-9126
Julia M KelliherBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0003-4100-9119
Austin J WattsBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0002-4329-1309
Samuel P MerrimanBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Grace VuyisichChemistry Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Laura M LilleyChemistry Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Kent E CoombsBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0003-0761-3670
Tara MastrenChemistry Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Munehiro TeshimaBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0001-8133-7411
Benjamin W SteinChemistry Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0002-0366-5476
Gregory L WagnerChemistry Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Srinivas IyerBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Andrew R M BradburySpecifica Inc., Santa Fe, NM, USA.ORCID 0000-0002-5567-8172
Jennifer Foster HarrisBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0001-7406-1904
Armand E DichosaBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0003-0640-6629
Stosh A KozimorChemistry Division, Los Alamos National Laboratory, Los Alamos, NM, USA.
Los Alamos National Laboratory · USSpecifica (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsHere, we describe a set of human monoclonal immunoglobulins (IgG1s) targeting

resultsTwo of our anti-F1 IgG (αF1Ig 2 and αF1Ig 8) stood out for high production yield, specificity, and stability. These two antibodies were additionally attractive in that they displayed picomolar affinity, did not compete when binding

conclusionThese antibodies are amenable to the development of accurate and sensitive diagnostics and immuno/radioimmunotherapeutics.

Indexed as

immunoantibioticimmunodiagnosticimmunotherapylateral flow assayLFAradioimmunotherapyradiolabelingRIT

Identifiers

PMID33294421
PMCPMC7716875
OpenAlexW3107933552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.